Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases

2018/01/31 by Christian C. Felder, Paul Goldsmith, Paul J. Goldsmith +6 · 2 citations
Biochemistry, Genetics and Molecular Biology · Neuroscience · #Receptor Mechanisms and Signaling #Neuroscience and Neuropharmacology Research #Nicotinic Acetylcholine Receptors Study

paper · doi:10.1016/j.neuropharm.2018.01.028

Citations

• Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease
• Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects

Cited by

• Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
• From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials